Authors
Jacob Y Hesterman, Robert F Hobbs, Ana P Kiess, Vicki Jardine, Eileen Sneeden, Jazmin Schwarz, Calvin Huntzinger, Diana Zepeda-Orozco, Oliver Sartor, George Sgouros, Radiopharmaceutical Therapy—Tissue Effects in the Clinic Committee
Published in
Journal of nuclear medicine : official publication, Society of Nuclear Medicine. Aug 13, 2026. Epub Aug 13, 2026.
Abstract
α-particle radiopharmaceutical therapy (α-RPT) is an emerging oncologic modality for treating malignancies, but its clinical development is hindered by limited datasets pairing patient-level dosimetry with prospectively collected toxicity and response endpoints. Additional challenges include radionuclide-specific imaging constraints, radioactive daughter redistribution, suborgan heterogeneity that decouples whole-organ absorbed dose from biologic effect, and uncertainty in relative biological effectiveness modeling. On behalf of the multidisciplinary Radiopharmaceutical Therapy-Tissue Effects in the Clinic committee, we review the literature on normal-organ dose and response assessment in α-RPT and propose a 2-stage framework to guide study design and data collection. Stage I emphasizes whole-organ dosimetry to support early safety characterization and derive preliminary organ toxicity reference levels. Stage II focuses on small-scale dosimetry and heterogeneity to enable more transferable, biologically informed reference levels. We offer practical recommendations for imaging feasibility, dosimetry workflows, toxicity endpoint selection (including delayed effects), and interpretation of dosimetry-toxicity relationships in early-phase trials, with the goal of standardizing data collection and accelerating the development of organ toxicity reference levels in α-RPT.
PMID:
42595489
Bibliographic data and abstract were imported from PubMed on 14 Aug 2026.
Read full publication at:
Please sign in
to see all details.
Advertisement
Stats
- Recommendations n/a n/a positive of 0 vote(s)
- Views 3
- Comments 0